Marketing: Page
-
FDA
Takeda renames antidepressant after name confusion leads to errors
Brintellix will now be marketed as Trintellix to distinguish it from AstraZeneca's Brilinta.
By Nicole Gray • May 3, 2016 -
Federal judge reopens high-stakes patent case between Merck and Gilead
Merck recently won $200 million in damages from Gilead after a federal jury upheld its patent claims tied to two hepatitis C drugs.
By Ned Pagliarulo • May 1, 2016 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineCommercialization
New drugs for obesity are becoming blockbusters, while Trump administration pressure is reshaping pharma marketing strategies ahead of looming patent cliffs.
By BioPharma Dive staff -
Crestor tumbles off patent cliff as first generic copy approved in US
AstraZeneca warned generic competition for the blockbuster cholesterol drug would likely hurt earnings in 2016.
By Nicole Gray • May 1, 2016 -
Canadian drugmaker tells CMS it can make cheaper version of cancer drug Xtandi
Made by Medivation and Astellas, Xtandi costs more than $129,000 per treatment in the U.S.
By Nicole Gray • April 29, 2016 -
Elizabeth Regan/BioPharma Dive
New Express Scripts program aims to react faster to spikes in drug prices
The major PBM also plans to expand indication-specific pricing for reimbursing drug costs.
By Nicole Gray • April 29, 2016 -
AstraZeneca debuts new tech along with approval of COPD inhaler
Bevespi will face a highly competitive U.S. respiratory market.
By Nicole Gray • April 27, 2016 -
Biogen's 'active woman' Tecfidera ad will go off air soon
The ad was criticized by some as unrealistic but it appears to have raised awareness of the drug.
By Nicole Gray • April 27, 2016 -
Deep Dive
Why Inflectra may face greater challenges than Zarxio in winning over US docs
The two drugs are the first biosimilars approved in the U.S., but others look set to join.
By Nicole Gray • April 27, 2016 -
Non-profit urges big pharma to take responsibility for drug take back programs
As You Sow has also put forward shareholder resolutions at J&J, AbbVie, and Merck, pushing the firms to pay for drug disposal.
By Nicole Gray • April 27, 2016 -
Seven New York insurers end restrictions on coverage for hepatitis C drugs
Under the terms of the deal with the New York Attorney General's office, the insurers must implement the changes within 45 days.
By Ned Pagliarulo • April 26, 2016 -
Viiv Healthcare expands access to HIV drug through patent pooling
Last month, parent company GlaxoSmithKline pledged not to seek patents for its drug in low-income countries.
By Nicole Gray • April 26, 2016 -
Proton pump inhibitors linked to serious kidney diseases in study
The study compared PPIs like AstraZeneca's Nexium to drugs known as H2 blockers.
By Nicole Gray • April 25, 2016 -
Germany mulling changes to limit prices drugmakers can charge
The country's universal healthcare system is generous in its drug coverage, but has been under pressure from increased prescription drug spending.
By Nicole Gray • April 25, 2016 -
New survey finds consumers unlikely to act on drug ads
Direct-to-consumer drug advertising has come under criticism from the American Medical Association and some lawmakers recently.
By Nicole Gray • April 21, 2016 -
Biosimilar update: Zarxio one year later
With Celltrion's Inflectra approval earlier this month, the U.S. biosimilar market could be heating up.
By Nicole Gray • April 20, 2016 -
New analysis boosts cost-effectiveness argument for Merck's Zepatier
Merck is competing to gain a share of the lucrative hepatitis C market.
By Nicole Gray • April 20, 2016 -
Indian pharma companies ramp up R&D to expand reach in US
A number of Indian companies have applied for more new drug approvals with the FDA.
By Nicole Gray • April 20, 2016 -
PhaseRX, Gemphire move forward with IPOs despite challenging market
Three biotechs have canceled planned IPOs in recent weeks.
By Nicole Gray • April 20, 2016 -
Study finds long-term health gains, cost-effectiveness benefits to new HPV vaccine
The newest form of Merck's Gardasil vaccine could decrease the incidence of cervical cancer from HPV by 73%.
By Nicole Gray • April 19, 2016 -
EASL 2016: Merck's 'no patient left behind' approach to hepatitis C
The company's hep c med Zepatier faces an uphill battle as it competes against Gilead's dominant treatments, leading Merck to look at typically untreated patient populations.
By Nicole Gray • April 18, 2016 -
Roche rules out quality problems with Avastin in India
In January, 15 patients in India were hospitalized with vision loss after using the drug off-label to treat macular degeneration.
By Nicole Gray • April 15, 2016 -
FDA
Most cancer drug labels don't include patient experiences: study
As a comparison, researchers found nearly 25% of other drugs included patient-reported outcomes information.
By Nicole Gray • April 15, 2016 -
Report: U.S. drug spending hit $310 billion last year
But prices on branded prescription drugs grew more slowly, increasing by 2.8% from 2014 levels.
By Ned Pagliarulo • April 14, 2016 -
Deep Dive
Biosimilars gain momentum — and pharma leaders are noticing
The FDA has approved two high-profile biosimilars and others await a decision. Respondents to BioPharma Dive’s first State of Drug Development survey picked up on this progress.
By Ned Pagliarulo • April 13, 2016 -
ICER questions cost effectiveness of multiple myeloma therapies
Some of the newer multiple myeloma drugs, including Amgen's Kyprolis, have cost effectiveness ratios above the accepted threshold for the Institute for Clinical and Economic Review.
By Nicole Gray • April 13, 2016
Previous
